China's brain-computer interface industry is rapidly advancing beyond research into commercial applications, with startups like NeuroXess and Gestala leading the charge. While Neuralink claims to be pioneering BCI technology, Chinese firms are leveraging stronger policy support, expanding clinical trials, and growing investor interest to accelerate development.

Provinces including Sichuan, Hubei, and Zhejiang have already established medical service pricing for BCI, paving the way for inclusion in national medical insurance. The government's August 2025 roadmap targets major technical milestones by 2027 and a complete supply chain by 2030. China's BCI market is projected to reach over $530 million in 2025, up from 3.2 billion yuan in 2024, with forecasts suggesting growth to 120 billion yuan by 2040.

Key drivers include strong cross-departmental policy support, vast clinical resources with lower research costs, mature industrial manufacturing capabilities, and strategic investment. Recent funding highlights include StairMed Technology's $48 million Series B and BrainCo's $287 million raise. As regulations align with international standards and data sovereignty concerns are addressed, China's BCI sector is positioned to challenge U.S. leaders like Neuralink, Synchron, and Paradromics in both invasive and noninvasive applications.